After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting--A single-institution experience.
2010
1136 Background: Trastuzumab received in 2006 the European Medicines Agency approval for the adjuvant treatment of patients affected by HER2-overexpressing early breast cancer after the results of ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI